menu
    • menu
    [{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Series C Financing","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Perception Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Perception Neuroscience \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"IntroSpect Digital Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"IntroSpect Digital Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IntroSpect Digital Therapeutics \/ atai","highestDevelopmentStatusID":"8","companyTruncated":"IntroSpect Digital Therapeutics \/ atai"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Perception Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ATAI Life Sciences \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Perception Neuroscience \/ atai Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ atai Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals for R-Ketamine

    Menu

    R-Ketamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : ATAI Life Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine...

                            Details : PCN-101 (R-ketamine), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-...

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2023

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : ATAI Life Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (...

                            Details : PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA receptor a...

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 13, 2023

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depre...

                            Details : PCN-101 (R-ketamine), demonstrated an encouraging safety profile and signals of efficacy across all timepoints despite not achieving statistical significance on the primary endpoint.

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 06, 2023

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neur...

                            Details : PCN-101 (R-ketamine) is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects.

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2022

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-1...

                            Details : PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA rec...

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 25, 2022

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Apeiron Investment Group

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntar...

                            Details : In the aggregate, these renewed lock-up agreements represent over 30% of atai’s outstanding common shares and illustrate the confidence of atai’s key shareholders in atai’s platform and its potential to address the growing mental health crisis incl...

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 15, 2021

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Apeiron Investment Group

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) For Treatment Resistant Depression

                            Details : Company initiate, Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine), a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as TRD.

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 14, 2021

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            IntroSpect Digital Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            IntroSpect Digital Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            atai Life Sciences and Introspect Digital Therapeutics to Test Novel Digital Therapeutic Approach in Patients ...

                            Details : Integration of Introspect’s digital therapeutic with R-ketamine therapy for patients with treatment resistant depression.

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 09, 2021

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Perception and Otsuka Enter Collaboration and Licensing Deal for Depression Drug Candidate

                            Details : Under the terms of the license, Otsuka will have exclusive rights to develop and commercialize products containing PCN-101 in Japan. Otsuka will undertake development, regulatory, and commercialization activities in Japan, with input and guidance from bo...

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            March 16, 2021

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Perception Neuroscience

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Perception Neuroscience's PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Stud...

                            Details : PCN-101 was safe and well-tolerated at all doses up to 150 mg, the highest dose tested. There were no serious adverse events reported. The pharmacokinetics of PCN-101 in plasma were approximately dose-proportional.

                            Brand Name : PCN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 19, 2021

                            Lead Product(s) : R-Ketamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth